Finding the dividend payers of the future
Professional investor Ken Wotton of the Baronsmead Venture Capital Trusts picks three small-cap stocks that should generate consistent dividend payments.
The wave of Covid-induced dividend cuts is forcing many British investors to re-evaluate their saving strategies. According to stockbroker AJ Bell, total dividend payments for 2020 are on course to be the lowest in six years – £63bn – with cuts estimated at £31.6bn. With £26.5bn – more than 80% – of the cuts coming from FTSE 100 firms, the current crisis has reminded investors of the importance of diversification. Historically, savers have relied on the blue-chip index, but there are plenty of income-generating small caps with more consistent payout policies.
Many investors assume that smaller companies are always more vulnerable to economic difficulties, but we look for companies dominant in niche markets that are relatively insulated from macro dynamics. Investors’ instinctive aversion to smaller companies means they can be neglected and thus offer us an attractive entry point. They are currently trading at a substantial discount to large caps.
A fantastic record of payout increases
Bioventix (Aim: BVXP), for instance, is a research-and-development company focused on producing antibodies for clinical diagnostics and pharmaceutical research. Thanks to its highly cash-generative business model, the £220m market cap company – which has a dividend yield of 2% – has a fantastic record of dividend increases: a 30% compound annual growth rate (CAGR) over five years. This means if you bought the shares on 1 July 2014, more than 80% of your original cost would have been returned in dividends and your capital would have appreciated by 750%.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Another little-known consistent dividend growth story is Anpario (Aim: ANP), an £85m market-cap natural animal-feed additive producer for global agriculture and aquaculture markets. The company offers a 2.3% dividend yield and has seen 12% dividend-per-share CAGR over the past five years. The dividend cover is well over two times.
Securing new income streams
While hunting down the market-cap spectrum can unearth dividend payers to alleviate the income drought, investors should not stay fixated on current payouts. Now is the time to focus on high-quality, promising businesses with the capacity to grow and pay dividends in the future.
The Baronsmead venture capital trust portfolios blend earlier-stage unquoted businesses, which provide access to capital growth, with more stable income-generating Aim stocks. This unique approach allows us to identify the dividend payers of the future while maintaining a regular income stream.
By taking smaller initial stakes in a broad range of early-stage companies we can manage downside risk as we assess the business growth potential. We then focus on the best companies, providing further capital and expertise. If a company scales up and becomes a listed reliable dividend payer, we can also invest in it through our other open-ended equity funds.
Ideagen (Aim: IDEA) is one company we have our eye on. The market-leading provider of governance, risk and compliance software already pays a dividend and, as it matures, will form an increasing proportion of our overall return. This is a stock we invested in originally at 19p in 2013. It now costs 172.5p.
Sign up to Money Morning
Our team, led by award winning editors, is dedicated to delivering you the top news, analysis, and guides to help you manage your money, grow your investments and build wealth.
Ken Wotton is lead manager of Strategic Equity Capital plc and Managing Director, Public Equity at Gresham House and leads the investment team managing public equity investments. Alongside this, he is manager for WS Gresham House UK Micro Cap Fund, WS Gresham House UK Multi Cap Income Fund and manages AIM listed portfolios on behalf of the Baronsmead VCTs. Ken graduated from Brasenose College, Oxford, before qualifying as a Chartered Accountant with KPMG. He was an equity research analyst with Commerzbank and then Evolution Securities prior to spending the past 12 years as a Fund Manager at Livingbridge and now Gresham House specialising in smaller companies.
-
Water companies blocked from using customer money to pay “undeserved” bonuses
The regulator has blocked three water companies from using billpayer money to pay £1.5 million in exec bonuses
By Katie Williams Published
-
Will the Bitcoin price hit $100,000?
With Bitcoin prices trading just below $100,000, we explore whether the cryptocurrency can hit the milestone.
By Dan McEvoy Published
-
Investing in a dangerous world: key takeaways from the MoneyWeek Summit
If you couldn’t get a ticket to MoneyWeek’s summit, here’s an overview of what you missed
By MoneyWeek Published
-
DCC: a top-notch company going cheap
DCC has a stellar long-term record and promising prospects. It has been unfairly marked down
By Jamie Ward Published
-
How investors can use options to navigate a turbulent world
Explainer Options can be a useful solution for investors to protect and grow their wealth in volatile times.
By James Proudlock Published
-
Will platinum and palladium rise?
Analysis Platinum and palladium have lagged gold and silver recently, but the outlook is improving. Should you invest?
By David J. Stevenson Published
-
Invest in Hilton Foods: a tasty UK food supplier
Hilton Foods is a keenly priced opportunity in an unglamorous sector
By Dr Matthew Partridge Published
-
HSBC stocks jump – is its cost-cutting plan already paying off?
HSBC's reorganisation has left questions unanswered, but otherwise the banking sector is in robust health
By Dr Matthew Partridge Published
-
Lock in an 11% yield with Sabre
Tips Sabre, a best-in-class company is undervalued due to low profits in the motor insurance industry. Should you invest?
By Rupert Hargreaves Published
-
James Halstead is a family firm going cheap but should you buy?
James Halstead will rebound from a weak patch, while tax changes would be a buying opportunity
By Jamie Ward Published